Vivani Medical Inc VANI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Vivani Medical Announces Participation in Upcoming Investor Conferences
-
Vivani Medical Announces Participation in Upcoming Investor Conferences
-
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
-
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
-
Vivani Medical Withdraws Record Date for Spin Off of Cortigent Subsidiary
Trading Information
- Previous Close Price
- $1.13
- Day Range
- $1.12–1.18
- 52-Week Range
- $0.92–1.81
- Bid/Ask
- $1.09 / $1.23
- Shares Outstanding
- 90.20M
- Market Cap
- $102.83M
- Volume/Avg
- 2,175 / 187,178
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 36
- Website
- https://www.vivani.com
Valuation
|
Metric
|
VANI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.37 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VANI
|
|---|---|
Quick Ratio | 3.09 |
Current Ratio | 3.25 |
Interest Coverage | — |
Quick Ratio
VANI
Profitability
|
Metric
|
VANI
|
|---|---|
Return on Assets (Normalized) | −70.33% |
Return on Equity (Normalized) | −207.87% |
Return on Invested Capital (Normalized) | −82.11% |
Return on Assets
VANI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?nN<B^ | LOCK|>RJ#M | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&K$WbVj | LOCK|#kf$T | $84B | |||
| Moderna Inc
MRNA
| LOCK|>xH<<%l | LOCK|&V | $83B | |||
| argenx SE ADR
ARGX
| LOCK|!%PwgH | LOCK|yj | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|q$!>TV! | LOCK|qwl | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|m>rj&N | LOCK|$X#g | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|l<YB?%m | LOCK|SZm$# | $29B | |||
| Incyte Corp
INCY
| LOCK|&SbR%$H | LOCK|N^ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|d%&gG< | LOCK|v$ | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|$$Wyb< | LOCK|>h | $14B |
United States